Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an update.
Ascletis Pharma Inc. announced promising preclinical results for its muscle-preserving weight loss drug candidate, ASC47, when combined with tirzepatide. In a study involving diet-induced obese mice, the combination demonstrated an 87% greater reduction in body weight compared to tirzepatide monotherapy, and significantly outperformed the combination with semaglutide. These findings suggest that ASC47, when used with tirzepatide, could potentially offer a more effective treatment for obesity, enhancing Ascletis’s position in the pharmaceutical industry and providing promising implications for stakeholders interested in obesity treatments.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company specializes in creating treatments for various health conditions, with a particular emphasis on obesity and related metabolic disorders. Ascletis develops proprietary drug candidates, such as ASC47, which is a muscle-preserving weight loss drug.
Average Trading Volume: 6,089,840
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.79B
For an in-depth examination of 1672 stock, go to TipRanks’ Overview page.